Erik Mortensen, NP
Adult Health · New York, NYNPI 1902055965
Payments from drug & device makers
Across 316 payments — averaging $30.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$5K
- Gilead$1K
- Merck$687
- EMD Serono, Inc.$372
- AbbVie$341
- Johnson & Johnson$340
- plus $2K from 20 others
What the payments were for
- Food & beverage$9,55198%
- Education$1482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 121 | $4,760 |
| Gilead | 52 | $1,376 |
| Merck | 23 | $687 |
| EMD Serono, Inc. | 20 | $372 |
| AbbVie | 15 | $341 |
| Johnson & Johnson(2 entities) | 16 | $340 |
| Theratechnologies Inc. | 9 | $338 |
| Janssen Scientific Affairs, LLC | 4 | $202 |
| Otsuka America Pharmaceutical, Inc. | 12 | $186 |
| Bausch Health US, LLC | 8 | $178 |
| Janssen Products, LP | 2 | $155 |
| Lilly USA, LLC | 6 | $130 |
| AstraZeneca | 6 | $122 |
| Antares Pharma, Inc. | 3 | $86 |
| Exact Sciences | 2 | $58 |
| Napo Pharmaceuticals Inc | 2 | $55 |
| Kowa Pharmaceuticals America, Inc. | 3 | $53 |
| Paratek Pharmaceuticals, Inc. | 2 | $48 |
| Nestle Healthcare Nutrition Inc. | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Octapharma USA, Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Biogen | 1 | $20 |
| Phadia US Inc. | 1 | $20 |
| Bio Products Laboratory USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,699 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SerostimSomatropin | 37 | $721,895 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 153 | $624,670 |
| TivicayDolutegravir Sodium | 130 | $373,097 |
| DescovyEmtricitabine/Tenofov Alafenam | 167 | $367,699 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 80 | $319,018 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 31 | $161,471 |
| DovatoDolutegravir Sodium/Lamivudine | 48 | $154,207 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 28 | $114,029 |
| RukobiaFostemsavir Tromethamine | 11 | $97,521 |
| PrezcobixDarunavir/Cobicistat | 22 | $85,348 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 20 | $74,151 |
| JulucaDolutegravir/Rilpivirine | 19 | $60,514 |
| EdurantRilpivirine Hcl | 34 | $46,117 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $41,410 |
| PifeltroDoravirine | 14 | $23,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya, Viread | $1,376 | $1,081,261352 claims |
| Viiv Healthcare CompanyTivicay, Triumeq, Dovato, Rukobia, Juluca | $4,760 | $1,004,357288 claims |
| EMD Serono, Inc.Serostim | $372 | $721,89537 claims |
| Janssen Products, LPSymtuza | $155 | $161,47131 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Trintellix | $28 | $120,70142 claims |
| Johnson & JohnsonPrezcobix | $340 | $85,34822 claims |
| Janssen Scientific Affairs, LLCEdurant | $202 | $46,11734 claims |
| MerckPifeltro, Isentress | $687 | $43,35325 claims |
| AstraZenecaSymbicort | $122 | $2,98113 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $53 | $2,21412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in New York
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Alyson HartyNew York$65K
- Laura GraaflandNew York$51K
- Allysa SaggeseNew York$49K
- Juliet EscalonNew York$46K
- Teshmanie RampersaudNew York$23K
- Jenna WenzelNew York$22K
- Elizabeth SavageNew York$20K
- Libby LevineNew York$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.